- NKTR-422 demonstrated inflammation
resolution and tissue repair in multiple preclinical models of
chronic inflammatory conditions -
SAN
FRANCISCO, Nov. 18, 2024 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) today announced its oral presentation
highlighting preclinical data on NKTR-422 at the 2024 American
College of Rheumatology (ACR) conference, being held in
Washington, D.C. from November 14-19, 2024.
NKTR-422 is a novel modified hematopoietic colony
stimulating factor (CSF) protein engineered to selectively modulate
resolution processes of inflammation by targeting the expansion,
reprograming and activation of anti-inflammatory tissue resident
macrophages.
Currently approved inflammatory disease therapies are not
designed to achieve inflammation resolution or tissue repair, which
are both required for remission.1 Nektar has identified
a CSF-1R agonist with a differentiated pharmacokinetic
(PK)/pharmacodynamic (PD) profile compared to the native CSF-1
cytokine. Reduced clearance enables sustained PD activity from a
single dose, unlike historical multiple dose per day necessary
regimens of recombinant human CSF-1 administration. This CSF-1R
agonist, NKTR-422, demonstrated inflammation resolution and tissue
repair markers induction in tissue resident macrophages without
induction of monocytosis and enhanced the efficacy of inflammatory
cytokine blockade in rodent models.
"These early data demonstrate that NKTR-422 has the potential to
accelerate treatment efficacy and may improve disease remission,
especially in combination treatments with standard of care
inflammatory cytokine blockade drugs," said Jonathan Zalevsky,
Ph.D., Senior Vice President and Chief Research & Development
Officer at Nektar. "We're excited to see how this program
progresses given its wide potential applications in a number of
therapeutic indications including acute and chronic
inflammation."
Details of the presentation can be found on Nektar's website at
www.nektar.com under Scientific Posters, Presentations and
Publications.
2024 American College of Rheumatology (ACR)
Convergence
Abstract 1866120: "A Novel Therapeutically Active CSF-1R
Agonist Promotes Tissue Macrophages Inflammation Resolution and
Induces Tissue Repair Pathways", Kivimae, S.
Presentation Type: Oral
Session: Abstracts: Cytokines & Cell Trafficking
Presentation Time: Monday, November
18 at 3:15 PM - 3:30 PM
EST
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company
focused on developing treatments that address the underlying
immunological dysfunction in autoimmune and chronic inflammatory
diseases. Nektar's lead product candidate, rezpegaldesleukin
(REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell
stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and
one in alopecia areata. Our pipeline also includes a preclinical
candidate NKTR-0165, which is a bivalent tumor necrosis factor
receptor type II agonist antibody. Nektar, together with various
partners, is also evaluating NKTR-255, an investigational IL-15
receptor agonist designed to boost the immune system's natural
ability to fight cancer, in several ongoing clinical trials. Nektar
is headquartered in San Francisco,
California. For further information, visit www.nektar.com
and follow us on LinkedIn.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements which can
be identified by words such as: "will," "expect," "develop,"
"potential," "advance," "anticipate," and similar references to
future periods. Examples of forward-looking statements include,
among others, statements regarding the therapeutic potential of,
and future development plans for NKTR-422. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs,
expectations and assumptions regarding the future of our business,
future plans and strategies, anticipated events and trends, the
economy and other future conditions. Because forward-looking
statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are
difficult to predict and many of which are outside of our control.
Our actual results may differ materially from those indicated in
the forward-looking statements. Therefore, you should not rely on
any of these forward-looking statements. Important factors that
could cause our actual results to differ materially from those
indicated in the forward-looking statements include, among others:
(i) our statements regarding the therapeutic potential of NKTR-422
are based on preclinical findings and observations and are subject
to change as research and development continue; (ii) NKTR-422 is an
investigational agent and continued research and development for
this drug candidate is subject to substantial risks, including
negative safety and efficacy findings in future clinical studies
(notwithstanding positive findings in earlier preclinical and
clinical studies); (iii) NKTR-422 is in preclinical development and
the risk of failure is high and can unexpectedly occur at any stage
prior to regulatory approval; (iv) the timing of the commencement
or end of clinical trials and the availability of clinical data may
be delayed or unsuccessful due to regulatory delays, slower than
anticipated patient enrollment, manufacturing challenges, changing
standards of care, evolving regulatory requirements, clinical trial
design, clinical outcomes, competitive factors, or delay or failure
in ultimately obtaining regulatory approval in one or more
important markets; (v) patents may not issue from our patent
applications for our drug candidates, patents that have issued may
not be enforceable, or additional intellectual property licenses
from third parties may be required; and (vi) certain other
important risks and uncertainties set forth in our Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission on
November 8, 2024. Any forward-looking
statement made by us in this press release is based only on
information currently available to us and speaks only as of the
date on which it is made. We undertake no obligation to update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
For Investors:
Vivian Wu of Nektar
Therapeutics
628-895-0661
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
- Ramírez-Valle, F., Maranville, J.C., Roy, S. et
al. Sequential immunotherapy: towards cures for
autoimmunity. Nat Rev Drug Discov 23,
501–524 (2024). https://doi.org/10.1038/s41573-024-00959-8
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-presents-first-preclinical-data-from-novel-csf-1-program-nktr-422-at-2024-american-college-of-rheumatology-acr-convergence-302307672.html
SOURCE Nektar Therapeutics